Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies

PharmacoEconomics

Volumn 33, Issue 4, 2015, Pages 341-353

  Jin, Huajie ^a   McCrone, Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; COMORBIDITY; COST BENEFIT ANALYSIS; COST OF ILLNESS; HEALTH CARE COST; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); AUSTRALIA; COST; DISEASE MANAGEMENT; ECONOMIC MODEL; ECONOMICS; EUROPEAN UNION; FACTUAL DATABASE; OUTCOME ASSESSMENT; TAIWAN; UNITED STATES;

AUSTRALIA; BIPOLAR DISORDER; COST OF ILLNESS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DIRECT SERVICE COSTS; DISEASE MANAGEMENT; EUROPEAN UNION; HUMANS; INCIDENCE; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); TAIWAN; UNITED STATES;

EID: 84926170407     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0250-y     Document Type: Review

References (104)

1. Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ. 2012;345:e8508. doi:10.1136/bmj.e8508.
2. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psych. 2011;68(3):241–51. doi:10.1001/archgenpsychiatry.2011.12.
3. Guilbert JJ. The world health report 2002: reducing risks, promoting healthy life. Educ Health. 2003;16(2):230.
4. Hirschfeld RMA, Vornik LA. Bipolar disorder: costs and comorbidity. Am J Manage Care. 2005;11(Suppl 3):S85–90.
5. Krishnan KRR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67(1):1–8.
6. McCrone P, Knapp M, King’s F, Patel A, Dhanasiri S. Paying the price: the cost of mental health care in England to 2026. King’s Fund. 2008;143:69–79.
7. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry. 2000;1(Suppl 13):38–41.
8. Lum TY, Parashuram S, Shippee TP, Wysocki A, Shippee ND, Homyak P, et al. Diagnosed prevalence and health care expenditures of mental health disorders among dual eligible older people. Gerontologist. 2013;53(2):334–44. doi:10.1093/geront/gns163.
9. Parker G, McCraw S, Hadzi-Pavlovic D, Fletcher K. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J Affect Disord. 2013;149(1–3):46–55. doi:10.1016/j.jad.2012.10.002.
10. Begley CE, Annegers JF, Swann AC, Lewis C, Coan S, Schnapp WB, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics. 2001;9(5 Pt I):483–95.
11. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4(6):398–405. doi:10.1034/j.1399-5618.2002.01148.x.
12. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry. 2002;180:227–33.
13. Rice DP. Cost of illness studies: what is good about them? J Int Soc Child Adolesc Injury Prev. 2000;6(3):177–9.
14. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71. doi:10.2165/11588380-000000000-00000.
15. Costa N, Derumeaux H, Rapp T, Garnault V, Ferlicoq L, Gillette S, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev. 2012;1:1–12.
16. Segel JE. Cost-of-illness studies: a primer. USA: RTI-UNC Center of Excellence in Health Promotion Economics RTI international; 2006. p. 1–39.
17. Kriza C, Emmert M, Wahlster P, Niederlander C, Kolominsky-Rabas P. Cost of illness in colorectal cancer: an international review. Pharmacoeconomics. 2013;31(7):577–88. doi:10.1007/s40273-013-0055-4.
18. Ian S, Marcello M, James T. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51–9.
19. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79. doi:10.1016/j.euroneuro.2011.08.008.
20. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79. doi:10.1016/j.euroneuro.2011.07.018.
21. Fajutrao L, Locklear J, Priaulx J, Heyes A. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health. 2009;5:3. doi:10.1186/1745-0179-5-3.
22. Patel A. The cost of mood disorders. Psychiatry. 2009;8(2):76–80. doi:10.1016/j.mppsy.2008.10.021.
23. Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, et al. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol. 2005;15(4):425–34.
24. Andlin-Sobocki P, Wittchen H. Cost of affective disorders in Europe. Eur J Neurol. 2005;12(s1):34–8. doi:10.1111/j.1468-1331.2005.01195.x.
25. Bauer M, Unutzer J, Pincus HA, Lawson WB. Bipolar disorder. Ment Health Serv Res. 2002;4(4):225–9. doi:10.1023/A:1020968616616.
26. Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Costs of bipolar disorder. Pharmacoeconomics. 2003;21(9):601–22.
27. Post RM. The impact of bipolar depression. J Clin Psychiatry. 2005;66(Suppl 5):5–10.
28. Stimmel GL. Economic grand rounds: the economic burden of bipolar disorder. Psychiatric Serv. 2004;55(2):117–8.
29. Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell’Osso MC, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148(2–3):161–9. doi:10.1016/j.jad.2013.02.001.
30. Fagiolini A, Chengappa KNR, Soreca I, Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs. 2008;22(8):655–69. doi:10.2165/00023210-200822080-00004.
31. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20(2):139–54. doi:10.1185/030079903125002801.
32. Montejano LB, Goetzel RZ, Ozminkowski RJ. Impact of bipolar disorder on employers: rationale for workplace interventions. Dis Manage Health Outcomes. 2005;13(4):267–80. doi:10.2165/00115677-200513040-00005.
33. Lothgren M. Economic evidence in affective disorders: a review. Eur J Health Econom. 2004;5(Suppl 1):S12–S20. doi:10.1007/s10198-005-0283-4.
34. Manning JS. Burden of illness in bipolar depression. Prim Care Comp J Clin Psychiatry. 2006;7(6):259–67.
35. Sajatovic M. Bipolar disorder: disease burden. Am J Manage Care. 2005;11(Suppl 3):S80–4.
36. Keck PE Jr, Kessler RC, Ross R. Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pract. 2008;14(Suppl 2):31–8.
37. Patel A. The cost of mood disorders. Psychiatry. 2006;5(4):141–5. doi:10.1383/psyt.2006.5.4.141.
38. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54(3):208–15. doi:10.1016/S0006-3223%2803%2900420-7.
39. Roijen L, Hoeijenbos M, Regeer E, ten Have M, Nolen W, Veraart C, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatrica Scandinavica. 2004;110(5):383–92. doi:10.1111/j.1600-0447.2004.00403.x.
40. Guo JJ, Keck Jr PE, Li H, Jang R, Kelton CML. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health. 2008;11(3):416–23. doi:10.1111/j.1524-4733.2007.00287.x.
41. Dusetzina SB, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA. Treatment use and costs among privately insured youths with diagnoses of bipolar disorder. Psychiatr Serv. 2012;63(10):1019–25. doi:10.1176/appi.ps.201100516.
42. Peele PB, Axelson DA, Xu Y, Malley EE. Use of medical and behavioral health services by adolescents with bipolar disorder. Psychiatr Serv. 2004;55(12):1392–6. doi:10.1176/appi.ps.55.12.1392.
43. Berry EA, Heaton PC, Kelton CML. National estimates of the inpatient burden of pediatric bipolar disorder in the United States. J Ment Health Policy Econom. 2011;14(3):115–23.
44. Gilmer T, Ojeda VD, Folsom D, Fuentes D, Criado V, Garcia P, et al. Costs of community-based public mental health services for older adults: variations related to age and diagnosis. Int J Geriatr Psychiatry. 2006;21(12):1121–6. doi:10.1002/gps.1616.
45. Rajagopalan K, Kleinman NL, Brook RA, Gardner HH, Brizee TJ, Smeeding JE. Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder. Curr Med Res Opin. 2006;22(3):443–52.
46. Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study. Psychiatr Res. 2011;190(1):10–14. doi:10.1016/j.psychres.2011.04.016.
47. Hong J, Reed C, Novick D, Haro JM, Windmeijer F, Knapp M. The cost of relapse for patients with a manicmixed episode of bipolar disorder in the emblem study. Pharmacoeconomics. 2010;28(7):555–66. doi:10.2165/11535200-000000000-00000.
48. De Zelicourt M, Dardennes R, Verdoux H, Gandhi G, Khoshnood B, Chomette E, et al. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. Pharmacoeconomics. 2003;21(15):1081–90. doi:10.2165/00019053-200321150-00002.
49. Olie JP, Levy E. Manic episodes: the direct cost of a three-month period following hospitalisation. Eur Psychiatry. 2002;17(5):278–86.
50. Tafalla M, Salvador-Carulla L, Saiz-Ruiz J, Diez T, Cordero L. Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain. BMC Psychiatry.2010;10:31. doi:10.1186/1471-244X-10-31.
51. Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther. 2002;24(10):1668–76.
52. Harley C, Li H, Corey-Lisle P, L’Italien GJ, Carson W. Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. Soc Psychiatr Psychiatr Epidemiol. 2007;42(9):690–7. doi:10.1007/s00127-007-0222-z.
53. Ohsfeldt RL, Lage MJ, Rajagopalan K. Medication use, service utilization, and medical costs associated with new episodes of bipolar disorder: evidence from a retrospective claims database. Prim Care Comp J Clin Psychiatry. 2007;9(4):280–6.
54. Tang C, Hsieh MH, Hung S, Lee IH, Lin Y, Yang YK. One-year post-hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population-based study. Bipolar Disord. 2010;12(8):859–65. doi:10.1111/j.1399-5618.2010.00878.x.
55. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M. Societal costs of bipolar disorder: the case of Sweden. Value in Health. ISPOR 13th Annual European Congress Prague Czech Republic, Start: 20101106 Conference End: 20101109.
56. Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord. 2002;71(1–3):131–9.
57. Stensland MD, Schultz JF, Frytak JR. Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis. J Clin Psychiatry. 2008;69(5):749–58. doi:10.4088/JCP.v69n0508.
58. Runge C, Grunze H. Annual costs of bipolar disorders in Germany [German]. Nervenarzt. 2004;75(9):896–903. doi:10.1007/s00115-004-1691-x.
59. Stang PE, Frank C, Kalsekar A, Yood MU, Wells K, Burch S. The clinical history and costs associated with delayed diagnosis of bipolar disorder. MedGenMed Medscape Gen Med. 2006;8(2):18.
60. Bagalman E, Muser E, Choi JC, Durden E, Macfadden W, Haskins JT, et al. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions [Erratum appears in Clin Ther. 2011 Dec;33(12):2093]. Clin Ther. 2011;33(10):1381–90.e4. doi:10.1016/j.clinthera.2011.09.005.
61. Durden E, Bagalman E, Muser E, Choi JC, Crivera C, Dirani R, et al. Characteristics, healthcare utilization and costs of bipolar disorder type i patients with and without frequent psychiatric intervention in a Medicaid population. J Med Econom. 2010;13(4):698–704. doi:10.3111/13696998.2010.531828.
62. Guo JJ, Keck PE, Li H, Patel NC. Treatment costs related to bipolar disorder and comorbid conditions among medicaid patients with bipolar disorder. Psychiatr Serv. 2007;58(8):1073–8. doi:10.1176/appi.ps.58.8.1073.
63. Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30(7):1358–74. doi:10.1016/S0149-2918%2808%2980062-8.
64. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805–11. doi:10.1176/appi.ps.52.6.805.
65. Williams MD, Shah ND, Wagie AE, Wood DL, Frye MA. Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis. Psychiatr Serv. 2011;62(9):1073–8. doi:10.1176/appi.ps.62.9.1073.
66. Centorrino F, Mark TL, Talamo A, Oh K, Chang J. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol. 2009;29(6):595–600. doi:10.1097/JCP.0b013e3181bef8a6.
67. Knoth RL, Chen K, Tafesse E. Datapoints: costs associated with the treatment of patients with bipolar disorder in a managed care organization. Psychiatric Serv (Washington, DC). 2004;55(12):1353.
68. Osby U, Tiainen A, Backlund L, Edman G, Adler M, Hallgren J, et al. Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. J Affect Disord. 2009;115(3):315–22. doi:10.1016/j.jad.2008.09.011.
69. Rice DP, Miller LS. The economic burden of affective disorders. Br J Psychiatry. 1995;(27):34–42.
70. Economics Access. Bipolar disorder: costs An analysis of the burden of bipolar disorder and related suicide in Australia. Canberra: Report for SANE Australia; 2002.
71. Busch AB, Yoon F, Barry CL, Azzone V, Normand SLT, Goldman HH, et al. The effects of mental health parity on spending and utilization for bipolar, major depression, and adjustment disorders. Am J Psychiatry. 2013;170(2):80–87. doi:10.1176/appi.ajp.2012.12030392.
72. Hsieh MH, Tang CH, Lee IH, Lai TJ, Lin YJ, Yang YK. Medical costs and vasculometabolic comorbidities among patients with bipolar disorder in Taiwan: a population-based and matched-control study. J Affect Disord. 2012;141(2–3):449–56. doi:10.1016/j.jad.2012.02.038.
73. Gonzalez-Pinto A, Dardennes R, de Zelicourt M, Lopez P, Oliveros R, Vieta E, et al. In-patient care costs of patients with bipolar 1 disorder: a comparison between two European centers. J Affect Disord. 2010;121(1–2):152–5. doi:10.1016/j.jad.2009.05.010.
74. Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry. 2006;67(8):1209–18.
75. Wyatt R, Henter I. An economic evaluation of manic-depressive illness-1991. Social Psychiatry Psychiatric Epidemiol. 1995;30(5):213–9.
76. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83. doi:10.1016/j.jad.2010.08.030.
77. Young AH, Rigney U, Shaw S, Emmas C, Thompson JM. Annual cost of managing bipolar disorder to the UK healthcare system. J Affect Disord. 2011;133(3):450–6. doi:10.1016/j.jad.2011.06.016.
78. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(Suppl 1):1–27.
79. Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–51. doi:10.1001/archgenpsychiatry.2011.12.
80. Ward MM, Javitz HS, Smith WM, Bakst A. A comparison of three approaches for attributing hospitalizations to specific diseases in cost analyses. Int J Technol Assess Health Care. 2000;16(1):125–36.
81. Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 Survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161–74.
82. Dittmann S, Biedermann NC, Grunze H, Hummel B, Scharer LO, Kleindienst N, et al. The Stanley Foundation Bipolar Network: results of the naturalistic follow-up study after 2.5 years of follow-up in the German centres. Neuropsychobiology. 2002;46(Suppl 1):2–9.
83. Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB et al. Prevalence and burden of bipolar disorders in European countries. Europ Neuropsychopharmacol. 2005;15(4):425–34.
84. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61(2):195–206.
85. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60(3):429–62.
86. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ. 2000;320(7245):1335.
87. Sanderson K, Andrews G, Corry J, Lapsley H. Reducing the burden of affective disorders: is evidence-based health care affordable? J Affect Disord. 2003;77(2):109–25.
88. Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatr. 2004;184:526–33.
89. NCCMH. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Leicester and London: The British Psychological Society and the Royal College of Psychiatrists [Full guideline]. 2006.
90. Berrios GE. The psychopathology of affectivity: conceptual and historical aspects. Psychol Med. 1985;15(4):745–58.
91. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
92. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th edn). Washington DC: APA; 1994.
93. Norlund A, Apelqvist J, Bitzen PO, Nyberg P, Schersten B. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med. 2001;250(1):57–65.
94. Pagano E, Brunetti M, Tediosi F, Garattini L. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics. 1999;15(6):583–95.
95. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics. 1992;2(1):1–4
96. Honeycutt A et al. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment–United States, 2003. Morb Mortal Weekly Rep. 2004;53(3):57–9.
97. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.
98. Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy. 1993;26(1):29–42.
99. Goeree R, O’Brien BJ, Blackhouse G, Agro K, Goering P. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Canadian Psychiatr - Revue Canadienne de Psychiatrie. 1999;44(5):455–63.
100. Stensland MD, Jacobson JG, Nyhuis A. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. J Affect Disord. 2007;101(1–3):187–93.
101. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med. 2003;45(1)5–14. doi:10.1097/00043764-200301000-00007.
102. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am psychiatr. 2003;160(7):1286–90.
103. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 1999;50(10):1303–8.
104. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62. doi:10.1111/j.1468-1331.2011.03590.x.